Psyence Biomedical (PBM) Stock Price

Psyence Biomedical Price

CLOSED
4.91
​
Market closed

Earnings per share have grown at 28.3% per year over the last 4 years.

Psyence Biomedical stock price

Access this data via the Eulerpool API

Psyence Biomedical business model & stock analysis

Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Frequently asked questions about Psyence Biomedical

Converted at the current exchange rate, the Psyence Biomedical share trades at 4.38 EUR (4.91 USD).

The revenue cannot currently be calculated for Psyence Biomedical.

The profit of Psyence Biomedical is -6.94 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Psyence Biomedical is currently -0.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Psyence Biomedical stock.

The P/S cannot be calculated for Psyence Biomedical currently.

The Eulerpool Quality Score for Psyence Biomedical is 2/10.

The ISIN of Psyence Biomedical is CA74449F4078. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Psyence Biomedical is PBM. The ticker symbol is used to trade Psyence Biomedical shares on the stock exchange.

Fair ValueTerminal
4.91 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website psyence.com
Country
Currency
USD
Initial public offering
Dec 10, 2021
ISIN
CA74449F4078
Cusip
74449F100
Market capitalization
11.29 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.67
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-40.94 %
Last updated Oct 10, 2026, 7:52 AM

Psyence Biomedical Peer Group